Dr. Schwieterman, is President and Chief Executive Officer of Mateon Therapeutics. Dr Schwieterman has assembled a world-class management team and is working to transform the organization into a leading oncology company.
Dr Schwieterman is a rheumatologist and board-certified internist, with more than 15 years of executive, regulatory, and drug development experience in the biopharmaceutical industry. He has been an independent consultant to multiple biotech and pharmaceutical clients where he helped them create their regulatory and clinical development strategies. Before joining Mateon, he was an employee of Perceptive Advisors, LLC, a hedge fund based in New York, New York. Dr Schwieterman was also the Chief Medical Officer of Chelsea Therapeutics, Inc., a publicly traded biopharmaceutical development company, where he led the clinical development team toward the approval of droxidopa (Northera™) for the treatment of symptomatic neurogenic orthostatic hypotension (a nonmotor symptom) associated with Parkinson’s disease and other neurogenerative diseases. Dr Schwieterman was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the Food and Drug Administration (FDA). In these capacities and others, Dr Schwieterman spent 10 years at the FDA in the Center for Biologics overseeing a wide range of clinical development plans for a large number of different types of molecules.
Dr Schwieterman holds a BS and MD from the University of Cincinnati.
Dr Chaplin is Chief Scientific Officer (CSO) of Mateon, bringing more than 30 years of experience in oncology research and drug development.
In addition to Dr Chaplin’s current role as CSO and Head of Research and Development at Mateon, he has also served as President and Chief Executive Officer. He has been a leader in the field of vascular targeting and was the first to discover the vascular disrupting action of CA4P (combretastatin A4-phosphate or fosbretabulin). His original work formed the basis for not only the development of CA4P with Mateon, but also the vascular targeting development programs at AstraZeneca and Aventis. Prior to his association with Mateon, Dr Chaplin was Vice President, Oncology at Aventis Pharma in Paris. Before the merger of Rhone Poulenc Rorer (RPR) with Hoechst Marion Roussell, Dr Chaplin was Senior Director of Oncology at RPR from 1998 to 1999. From 1992 to 1998, Dr Chaplin led the Cancer Research Campaign’s (CRC) Tumor Microcirculation Group, based at the Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, London. Dr Chaplin also served as Section Head of Cancer Biology at Xenova in the United Kingdom and held a senior staff appointment at the British Columbia Cancer Research Centre.
Educated in the United Kingdom, Dr Chaplin has a BSc in chemistry from the University of Essex, a MSc in pharmacology from the University of Southampton, and a PhD in tumor biology from the University of London.
Mr Loar is the Chief Financial Officer (CFO) of Mateon, bringing more than 20 years of experience as a financial executive with financial and accounting experience in both public and private companies in the biopharmaceutical industry.
Mr Loar was most recently CFO of KineMed, Inc., from January 2014 to July 2015. From January 2010 to January 2014, he was an independent financial consultant to companies in the biopharmaceutical industry. While consulting, he also served as acting Chief Executive and Financial Officer of Neurobiological Technologies, Inc. (NTI), beginning in February 2010, and as CFO of Virolab, Inc., from May 2011 to August 2012. Previously, he was CFO of NTI from April 2008 to December 2009. Earlier in his career, Mr Loar was CFO of Osteologix, Inc., from 2006 to 2008 and of Genelabs Technologies, Inc., from 1995 to 2006. Mr Loar currently serves on the board of directors of NTI.
He received a BA in legal studies from the University of California, Berkeley, and is a certified public accountant (inactive) in California.